Turbine, a simulation-first drug discovery company, today announced the formation of its Scientific Advisory Board (SAB) with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge. The first members of the SAB together bring 70 years of pharma and biotech leadership expertise and drug development insight, with over 20 approved drugs between them. The globally recognised scientists will help Turbine transform the costly and failure-prone oncology drug R&D into a series of rational steps, guided by the company’s AI-powered simulation platform.
Turbine aims to redesign anticancer drug discovery and development by simulating complex biological problems before crucial points at which drug discovery programmes usually fail today. Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge will play an instrumental role in Turbine’s endeavour, employing decades of global industry experience advancing scientific research through clinical development, regulatory approval, and incorporating research into healthcare systems. Having led teams and programmes across biotech and pharma, the newly appointed SAB members understand the complexity of cancer biology and the translational challenges of drug discovery. Serving as scientific advisors, they will help Turbine grow their simulation-based oncology pipeline relying on the Company’s Simulated Cell technology. This proprietary simulation platform has the capacity to uncover novel biology while cutting the cost and time of discovery compared to wet lab-heavy methods.
Dr. Annalisa Jenkins commented: “The use of AI-enhanced technology combined with scientific wisdom and guidance from pharma R&D expertise is a step change opportunity to shape the future of the industry. I am delighted to join forces with this young, entrepreneurial team at Turbine, who have already made remarkable progress demonstrating the value of their simulation-first discovery platform through collaborations with pharmaceutical companies.”